title: Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells.
abstract: BACKGROUND
  Despite natural killer (NK) cells being originally identified and named because of their ability to kill tumor cells in vitro, only limited information is available on NK cells infiltrating malignant tumors, especially in humans.
  
  
  METHODS
  NK cells infiltrating human nonsmall cell lung cancers (NSCLC) were analyzed with the aim of identifying their potential protective role in an antitumor immune response. Both relevant molecule expression and functions of NK cells infiltrating NSCLC were analyzed in comparison with autologous NK cells isolated from either peritumoral normal lung tissues or peripheral blood.
  
  
  RESULTS
  The CD56 bright CD16(-) NK cell subset was consistently observed as being highly enriched in tumor infiltrate and displayed activation markers, including NKp44, CD69, and HLA-DR. Remarkably, the cytolytic potential of NK cells isolated from cancer tissues was lower than that of NK cells from peripheral blood or normal lung tissue, whereas no difference was observed regarding their capability of producing cytokines. With regard to their localization within tumor, NK cells were found in tumor stroma, whereas they were not in direct contact with cancer cells.
  
  
  CONCLUSIONS
  For the first time NK cells infiltrating NSCLC have been characterized and it is shown that they are mainly capable of producing relevant cytokines rather than exerting direct cancer cell killing.
authors.affiliation: Department of Experimental Medicine, University of Genoa, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Carrega
authors.forename: Barbara
authors.initials: B
authors.lastname: Morandi
authors.forename: Roberta
authors.initials: R
authors.lastname: Costa
authors.forename: Guido
authors.initials: G
authors.lastname: Frumento
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Forte
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Altavilla
authors.forename: Giovanni Battista
authors.initials: GB
authors.lastname: Ratto
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Mingari
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Moretta
authors.forename: Guido
authors.initials: G
authors.lastname: Ferlazzo
mesh_terms: D019002:CD56 Antigen / Q000276:immunology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D016207:Cytokines / Q000032:analysis; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D007694:Killer Cells, Natural / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D052118:Lysosomal-Associated Membrane Protein 1 / Q000276:immunology; D054353:Perforin / Q000032:analysis; D017452:Receptors, IgG / Q000276:immunology*; D054340:Receptors, KIR / Q000032:analysis
chemical_list: D019002:CD56 Antigen; D016207:Cytokines; D052118:Lysosomal-Associated Membrane Protein 1; D017452:Receptors, IgG; D054340:Receptors, KIR; D054353:Perforin